Prior studies using radiolabeled 169 cDb in syngeneic murine colon and mammary tumors treated with anti-PD-1, anti-CD137, or CpG oligonucleotide immunotherapy showed roughly twofold higher uptake of the diabody in treated tumors relative to non-treated control tumors. Here, TNFRSF9 is linked to breast cancer.